Surrozen, Inc. SRZN
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Surrozen, Inc. (SRZN) is a healthcare company listed in the US with a market value of about $603M. In the twelve months to September 30, 2026 it had revenue of $11M and net income of -$390M, a net margin of -3706.4%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -56%.
About Surrozen
Surrozen is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $12M in 2022 to $3M in 2025, a decline of about 34.7% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 223% over three years (dilution for shareholders). It spends 845% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $11M | $3M | $11M | $0 | $12M | $0 | — |
| Net income | -$390M | -$242M | -$64M | -$43M | -$36M | -$55M | -$33M |
| Free cash flow | -$31M | -$30M | -$18M | -$41M | -$45M | -$50M | -$30M |
| EPS (diluted) | $-46.96 | $-32.37 | $-21.67 | $-21.33 | $-15.56 | $-33.16 | $-30.73 |
| Net margin | -3706.4% | -6960.8% | -596.6% | — | -288.0% | — | — |
| ROIC | — | — | — | -87.5% | -42.9% | -36.6% | -45.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $63.50, 101% above the current price; targets range from $54.00 to $80.00; the consensus rating is “Strong buy”; expected EPS is $-18.78 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Surrozen pay a dividend?
Not currently.
Is Surrozen a good stock to buy?
We do not give buy or sell advice. Surrozen scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.